The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, recently conducted official visits to several pharmaceutical facilities and research centers in the United States. The visits aimed to review the latest advancements in the global pharmaceutical industry and leverage international expertise to advance scientific research and innovation in the pharmaceutical field.

The CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham S. Aljadhey, conducted a series of site visits to specialized medical and research centers in the United States. The visits aimed to leverage global expertise in the latest technologies and developments within advanced therapies and biotechnology. They took place on the sidelines of Dr. Aljadhey’s participation in the Drug Information Association (DIA) Annual Meeting in Philadelphia, Pennsylvania.

The Saudi Food and Drug Authority (SFDA) has officially announced the opening of submissions for its sixth annual Regulatory Research Day 2026. The event, scheduled to take place this November at the SFDA headquarters in Riyadh, will feature scientific contributions from researchers.

The SFDA stated that the submission window for scientific posters is open from June 15 to September 17, 2026. The Authority invites scientists and researchers to submit their work in accordance with the event's approved themes.

The Saudi Food and Drug Authority (SFDA) has activated the Regulatory AI System for Incoming Drugs (RASID) service to support regulatory operations at entry points for arriving pilgrims during the Hajj season. It aims to enhance the efficiency and accuracy of smart verification processes for controlled medications, significantly improving the overall pilgrim experience while optimizing border regulatory operations.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, extended his congratulations to the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, on the success of the 1447 AH Hajj season, which was marked by integrated services, exemplary performance, and comprehensive care provided to the guests of Allah.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, extended his warmest congratulations to the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, on the occasion of Eid al-Adha; praying to Allah to bless the Kingdom, and the Arab and Islamic nations with goodness and prosperity.

The Saudi Food and Drug Authority (SFDA) has granted Novo Nordisk Breakthrough designation to (FREHEMGO), which is indicated as a long-term routine prophylaxis of bleeding episodes in all age groups patients with hemophilia A with or without FVIII inhibitors.

H.E. Mr. Fahad bin Abdulrahman Al-Jalajel, Minister of Health and Chairman of the Board of Directors of the Saudi Food and Drug Authority (SFDA), visited the SFDA's Hajj Operations Center in Makkah today. The visit aimed to ensure the efficiency of services and evaluate ongoing efforts to enhance the safety of products provided to pilgrims during the Hajj season.

The CEO of the Saudi Food and Drug Authority (SFDA), H.E. Dr. Hisham S. Aljadhey, conducted an inspection tour of several facilities within the SFDA's jurisdiction in the Makkah region. This visit was part of a comprehensive effort to evaluate the readiness of regulatory and field operations prior to the Hajj season 1447 AH.

During the tour, Dr. Aljadhey reviewed the preparedness of key regulatory procedures designed to ensure the safety, quality, and compliance of all food, pharmaceutical, and medical products with Saudi Arabia’s standards.

The Saudi Food and Drug Authority (SFDA) has revealed the results of its pre-Hajj campaign for the 1447 AH Hajj season, which targeted establishments under its supervision across the Makkah and Madinah regions. The campaign demonstrated advanced levels of regulatory readiness and operational efficiency, reflecting high compliance among facilities and significantly enhancing the safety of food, drugs, and medical products provided to pilgrims.